Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Other Accumulated Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Other Accumulated Expenses data on record, last reported at $144000.0 in Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 55.56% to $144000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $144000.0, a 55.56% decrease, with the full-year FY2025 number at $6000.0, down 98.72% from a year prior.
  • Other Accumulated Expenses reached $144000.0 in Q1 2026 per RAPP's latest filing, up from $6000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for RAPP hit a ceiling of $469000.0 in Q4 2024 and a floor of $6000.0 in Q4 2025.
  • A 4-year average of $208666.7 and a median of $144000.0 in 2026 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 311.4% in 2024, then plummeted 98.72% in 2025.
  • Tracing RAPP's Other Accumulated Expenses over 4 years: stood at $114000.0 in 2023, then skyrocketed by 311.4% to $469000.0 in 2024, then tumbled by 98.72% to $6000.0 in 2025, then surged by 2300.0% to $144000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for RAPP at $144000.0 in Q1 2026, $6000.0 in Q4 2025, and $104000.0 in Q3 2025.